H Malik1, A Z Khan2, D P Berry3, I C Cameron4, I Pope5, D Sherlock6, S Helmy7, B Byrne8, M Thompson9, A Pulfer10, B Davidson7. 1. University Hospital Aintree, Liverpool, UK. 2. Royal Marsden Hospital, London, UK. 3. University Hospital of Wales, Cardiff, UK. 4. Nottingham University Hospitals, Nottingham, UK. 5. University Hospitals Bristol NHS Trust, Bristol, UK. 6. Pennine Acute NHS Trust, Manchester, UK. 7. Royal Free London NHS Foundation Trust, London, UK. 8. Merck Serono Ltd., Feltham, UK. 9. Formerly of Merck Serono Ltd., Feltham, UK. 10. pH Associates Ltd., Marlow, Bucks, UK. Electronic address: amandapulfer@phassociates.com.
Abstract
AIMS: The high objective response rate to cetuximab along with chemotherapy in patients with colorectal liver metastases makes it an effective downsizing protocol to facilitate surgery in those with initially unresectable disease. Adoption of this strategy has been variable in the UK. A retrospective observational study was conducted in 7 UK specialist liver surgical centres to describe the liver resection rate following a downsizing protocol of cetuximab and chemotherapy and to evaluate the quality and efficiency of processes by which the treatment was provided. METHODS: Data were collected in 2012 by reviewing medical records of patients with colorectal metastases confined to the liver, defined as unresectable without downsizing therapy at first review by a specialist Multi Disciplinary Team (MDT). RESULTS: Sixty patients were included; 29 (48%) underwent liver resection following cetuximab and chemotherapy. Of the 29, 17 (59% or 28% of all patients) achieved R0 resection and 7 (24% or 12% of all patients) R1 resection. All treated patients were KRAS wild-type. CONCLUSION: In specialist liver surgical centres, where patients are evaluated for liver resection, optimal management by MDT using KRAS testing, cetuximab and chemotherapy results in a 28% R0 resection rate in patients with initially unresectable colorectal cancer liver metastases.
AIMS: The high objective response rate to cetuximab along with chemotherapy in patients with colorectal liver metastases makes it an effective downsizing protocol to facilitate surgery in those with initially unresectable disease. Adoption of this strategy has been variable in the UK. A retrospective observational study was conducted in 7 UK specialist liver surgical centres to describe the liver resection rate following a downsizing protocol of cetuximab and chemotherapy and to evaluate the quality and efficiency of processes by which the treatment was provided. METHODS: Data were collected in 2012 by reviewing medical records of patients with colorectal metastases confined to the liver, defined as unresectable without downsizing therapy at first review by a specialist Multi Disciplinary Team (MDT). RESULTS: Sixty patients were included; 29 (48%) underwent liver resection following cetuximab and chemotherapy. Of the 29, 17 (59% or 28% of all patients) achieved R0 resection and 7 (24% or 12% of all patients) R1 resection. All treated patients were KRAS wild-type. CONCLUSION: In specialist liver surgical centres, where patients are evaluated for liver resection, optimal management by MDT using KRAS testing, cetuximab and chemotherapy results in a 28% R0 resection rate in patients with initially unresectable colorectal cancer liver metastases.
Authors: Alexander Massmann; Thomas Rodt; Steffen Marquardt; Roland Seidel; Katrina Thomas; Frank Wacker; Götz M Richter; Hans U Kauczor; Arno Bücker; Philippe L Pereira; Christof M Sommer Journal: Langenbecks Arch Surg Date: 2015-06-19 Impact factor: 3.445
Authors: B Garlipp; P Gibbs; G A Van Hazel; R Jeyarajah; R C G Martin; C J Bruns; H Lang; D M Manas; G M Ettorre; F Pardo; V Donckier; C Benckert; T M van Gulik; D Goéré; M Schoen; J Pratschke; W O Bechstein; A M de la Cuesta; S Adeyemi; J Ricke; M Seidensticker Journal: Br J Surg Date: 2019-08-19 Impact factor: 6.939
Authors: Shailendra Shah; Shaolan Qin; Yang Luo; Yizhou Huang; Ran Jing; Jay N Shah; Jianjun Chen; Huimin Chen; Ming Zhong Journal: Front Cell Dev Biol Date: 2021-03-25
Authors: Sanne Nieuwenhuizen; Madelon Dijkstra; Robbert S Puijk; Bart Geboers; Alette H Ruarus; Evelien A Schouten; Karin Nielsen; Jan J J de Vries; Anna M E Bruynzeel; Hester J Scheffer; M Petrousjka van den Tol; Cornelis J A Haasbeek; Martijn R Meijerink Journal: Curr Oncol Rep Date: 2022-03-17 Impact factor: 5.945